| Literature DB >> 28706259 |
Yi Yang1,2, Handan Tan1, Bolin Deng1, Hongsong Yu1, Guannan Su1, Jiayue Hu1, Qingfeng Cao1, Gangxiang Yuan1, Aize Kijlstra3, Peizeng Yang4.
Abstract
C-type lectin receptors (CLRs) have been demonstrated to be involved in several autoimmune diseases. The role of CLRs in Behcet's disease (BD) is unknown and thus was the purpose of this study. A two-stage association study was carried out and a total of 766 BD patients and 1674 healthy controls were recruited. Genotyping of 14 SNPs of 13 genes in CLRs was carried out by iPLEX Gold genotyping or polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. The expression of mannose binding lectin 2 (MBL2) and killer cell lectin like receptor C4 (KLRC4) was measured by Real-time PCR. Significantly increased frequencies of the A allele as well as AA genotype of rs1800450 in MBL2 (Pc = 2.50 × 10-6, OR = 1.494; Pc = 2.24 × 10-6,OR = 2.899; respectively) and TT genotype of rs2617170 in KLRC4 (Pc = 2.53 × 10-6, OR = 1.695) and decreased frequencies of GG genotype of rs1800450 (Pc = 1.56 × 10-3, OR = 0.689) and C allele as well as CC genotype of rs2617170 (Pc = 2.05 × 10-9,OR = 0.664; Pc = 1.20 × 10-5, OR = 0.585; respectively) were observed in BD. Two variants, p.Gly54Asp (rs1800450) and p.Asn104Ser (rs2617170) affect MBL2 and KLRC4 protein stability and expression. Our study demonstrates that the MBL2/rs1800450 and KLRC4/rs2617170 are susceptibility factors for BD in a Chinese Han population.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28706259 PMCID: PMC5509750 DOI: 10.1038/s41598-017-05877-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Clinical features, age, and sex distribution of BD patients and healthy controls.
| Clinical features | total | % |
|---|---|---|
| Patients with BD | 766 | |
| Mean age ± SD | 33.7 ± 8.9 | |
| Male | 663 | 86.6 |
| Female | 103 | 13.4 |
| Uveitis | 766 | 100 |
| Oral ulcer | 766 | 100 |
| Genital ulcer | 454 | 59.3 |
| Skin lesions | 605 | 79 |
| Arthritis | 122 | 15.9 |
| Positive pathergy test | 123 | 16.1 |
| Healthy controls | 1674 | |
| Mean age ± SD | 39.5 ± 10.7 | |
| Male | 938 | 56 |
| Female | 736 | 44 |
Genotype and allele frequencies of MBL2 and KLRC4 polymorphisms in BD and healthy controls.
| Gene | SNP | Allele | BD | % | Controls | % | P Value | Pc Value | OR(95%CI) |
|---|---|---|---|---|---|---|---|---|---|
| Genotype | N | N | |||||||
| MBL2 | rs1800450 | ||||||||
| stage1 | A | 188 | 24.2 | 284 | 19.1 | 5 × 10−3 | 0.26 | 1.351 (1.096–1.665) | |
| G | 588 | 75.8 | 1200 | 80.9 | |||||
| AA | 32 | 8.2 | 25 | 3.4 | 4.25 × 10−4 | 0.02 | 2.556 (1.492–4.308) | ||
| AG | 124 | 32 | 234 | 31.5 | 0.885 | NS | 1.020 (0.783–1.327) | ||
| GG | 232 | 59.8 | 483 | 65.1 | 0.079 | NS | 0.797 (0.619–1.027) | ||
| stage2 | A | 198 | 26.2 | 332 | 17.8 | 1.31 × 10−6 | 6.70 × 10−5 | 1.637 (1.339–2.002) | |
| G | 558 | 73.8 | 1532 | 82.2 | |||||
| AA | 26 | 6.9 | 21 | 2.3 | 4.54 × 10−5 | 2.32 × 10−3 | 3.204 (1.780–5.769) | ||
| AG | 146 | 38.6 | 290 | 31.1 | 0.009 | NS | 1.391 (1.084–1.785) | ||
| GG | 206 | 54.5 | 621 | 66.6 | 3.72 × 10−5 | 1.90 × 10−3 | 0.6 (0.470–0.766) | ||
| combined | A | 386 | 25.2 | 616 | 18.4 | 4.90 × 10−8 | 2.50 × 10−6 | 1.494 (1.293–1.726) | |
| G | 1146 | 74.8 | 2732 | 81.6 | |||||
| AA | 58 | 7.6 | 46 | 2.7 | 4.39 × 10−8 | 2.24 × 10−6 | 2.899 (1.949–4.312) | ||
| AG | 270 | 35.2 | 524 | 31.3 | 5.40 × 10−2 | NS | 1.195 (0.997–1.431) | ||
| GG | 438 | 57.2 | 1104 | 65.9 | 3.06 × 10−5 | 1.56 × 10−3 | 0.689 (0.579–0.821) | ||
| KLRC4 | rs2617170 | ||||||||
| stage1 | C | 342 | 44.1 | 807 | 54.4 | 3.25 × 10−6 | 1.66 × 10−4 | 0.661 (0.555–0.787) | |
| T | 434 | 55.9 | 677 | 45.6 | |||||
| CC | 79 | 20.4 | 228 | 30.7 | 2.00 × 10−4 | 1.02 × 10−2 | 0.576 (0.430–0.772) | ||
| CT | 184 | 47.4 | 351 | 47.3 | 0.97 | NS | 1.005 (0.786–1.285) | ||
| TT | 125 | 32.2 | 163 | 22 | 1.74 × 10−4 | 8.90 × 10−3 | 1.688 (1.283–2.222) | ||
| stage2 | C | 333 | 44 | 1009 | 54.1 | 2.89 × 10−6 | 1.47 × 10−4 | 0.667 (0.563–0.791) | |
| T | 423 | 56 | 855 | 45.9 | |||||
| CC | 77 | 20.4 | 281 | 30.2 | 3.19 × 10−4 | 1.63 × 10−2 | 0.593 (0.445–0.789) | ||
| CT | 179 | 47.4 | 447 | 48 | 0.84 | NS | 0.976 (0.768–1.240) | ||
| TT | 122 | 32.3 | 204 | 21.9 | 8.16 × 10−5 | 4.16 × 10−3 | 1.701 (1.304–2.218) | ||
| combined | C | 675 | 44.1 | 1816 | 54.2 | 4.03 × 10−11 | 2.05 × 10−9 | 0.664 (0.588–0.750) | |
| T | 857 | 55.9 | 1532 | 45.8 | |||||
| CC | 156 | 20.4 | 509 | 30.4 | 2.35 × 10−7 | 1.20 × 10−5 | 0.585 (0.477-0.718) | ||
| CT | 363 | 47.4 | 798 | 47.7 | 0.897 | NS | 0.989 (0.833–1.173) | ||
| TT | 247 | 32.2 | 367 | 21.9 | 4.96 × 10−8 | 2.53 × 10−6 | 1.695 (1.401–2.051) |
SNP, single-nucleotide polymorphism; BD, Behcet’s disease; OR, odds ratio; NS, not significant; 95% CI, 95% confidence interval; Pc, Bonferroni corrected p value.
Figure 1The influence of MBL2/rs1800450 genotypes on the expression of MBL2 by PBMCs. MBL2 mRNA level in GG individuals of SNP rs1800450 was significantly higher than in AG individuals. Data are shown as mean ± SD. *P = 0.019 (GG/AG = 12).
Figure 2The influence of KLRC4/rs2617170 genotypes on the expression of KLRC4 in PBMCs. KLRC4 mRNA level in CC individuals of SNP rs2617170 was significantly higher than in CC/CT individuals. Data are shown as mean ± SD. **P < 0.001 (CC = 13, CT = 11, TT = 10).
Figure 3Effect of MBL2 genotype on cytokine production by LPS stimulated PBMCs from healthy genotyped individuals. IFN-γ (a), IL-6 (b), IL-8(c), IL-1β (d), IL-10 (e) and TNF-α (f) were measured by ELISA in the cell culture supernatants. Date expressed as the mean ± SD (AG/GG = 12).
Figure 4Effect of KLRC4 genotype on cytokine production by LPS stimulated PBMCs from healthy genotyped individuals. IL-8 (a), IL-10 (b), IL-1β (c), IFN-γ (d), IL-6 (e) and TNF-α (f) were measured by ELISA in the cell culture supernatants. Data are expressed as the mean ± SD (CC = 10, CT = 10, TT = 8).
Primers applied in the analysis of iPLEX Gold genotyping in the CLR related genes.
| SNP_ID | 2nd-PCRP | 1st-PCRP | UEP_SEQ |
|---|---|---|---|
| MBL2 | |||
| rs7096206 | ACGTTGGATGACCTGGGTTTCCACTCATTC | ACGTTGGATGTTCATCTGTGCCTAGACACC | TGTTCTCACTGCCAC |
| CD69 | |||
| rs4763879 | ACGTTGGATGTGTTGCATGTATCAGTTGTC | ACGTTGGATGTGCAAGAATGCTCCTAGCAG | TTGTCTTATTTTGAATTGCTGAG |
| SFTPD | |||
| rs911887 | ACGTTGGATGCCCTGTATACAGACTTCTCC | ACGTTGGATGAAAGGCAGAGGTGGTATCGC | aaccGACTTCTCCATTGCTTGCGCC |
| KLRD1 | |||
| rs2302489 | ACGTTGGATGAGCTGAGCTGGAGATTAAAG | ACGTTGGATGGAGGCTTGTGATTCTACTGC | ttAGTATGAAGAAATTTAGCAAAAA |
| KLRC4 | |||
| rs2617170 | ACGTTGGATGTTTTGCATCCCTTTAGAGAC | ACGTTGGATGAGGTATTGGAGTACTGGAGC | gttcgGCATTCTTCTATTCAGGGAAAAA |
| CD209 | |||
| rs2287886 | ACGTTGGATGATTCTTGAAAGATCCGGCCC | ACGTTGGATGTCCCACCCTGTGATCTTTAC | TCTGATGCTTTCCACTAG |
| KLRB1 | |||
| rs4763655 | ACGTTGGATGCCTGACCCCAGTGTATTATG | ACGTTGGATGTCTCACATTAGGATGCTCAC | ttTTCTATCTCCTCAGGGC |
| CLEC12A | |||
| rs1323461 | ACGTTGGATGGAGTTTAGGCACTCAGATCC | ACGTTGGATGTTTCTGACCCACACTCCTAC | ggccGATCCCTGCATACTCAT |
| KLRK1 | |||
| rs2255336 | ACGTTGGATGGCAATCTACTTCTCTGTTGTC | ACGTTGGATGTTTCTGCTGCTTCATCGCTG | AGGAATACAGCACTCCATATTG |
| CLEC4A | |||
| rs2377422 | ACGTTGGATGCCTCCCTACCTTTCATTTGC | ACGTTGGATGGGAAGAGGACTAAGTAACCC | ATTTCACTAAAACCATCCCTAAA |
| CLEC2D | |||
| rs3764022 | ACGTTGGATGCCTCTAGTGAAAAGCGAAGG | ACGTTGGATGAAGCGCCAAATTAAGGTAGC | TTTCAATAATTTTTTCCAGGTTGT |
| KLRC1 | |||
| rs2734440 | ACGTTGGATGAGGACAATGGCCACAATGAC | ACGTTGGATGCAGCCCATGAAGATGTATAG | CATATTTGCAAACATATAAACCTATA |
| KLRG1 | |||
| rs1121401 | ACGTTGGATGAGTGACCTATGAACAATGCC | ACGTTGGATGATACCTGTAGGTTGTATCCC | AATAGTATAACAAAAGTGAAACTG |